5W report finds cannabis brands struggle for AI visibility amid compliance filters

Cannabis brands are running into a new gatekeeper: AI systems that hedge, refuse or narrow their answers when the category looks risky. In 5W’s Cannabis AI Visibility Index 2026, about 28% of cannabis prompts triggered refusals, hedges or prominent disclaimers, the highest rate the firm has measured in any consumer category.

The index tested more than 50 consumer-intent prompts across ChatGPT, Claude, Perplexity and Google AI Overviews in the first quarter of 2026. 5W split the category into five segments: U.S. multi-state operators, branded cannabis consumer products, CBD-specific brands, dispensary aggregators and tech, and ancillary services. The firm says cannabis is the most legally fragmented major consumer category in America, with federal Schedule I status layered over 25 state adult-use regimes and 16 medical-only regimes.

That fragmentation showed up in the rankings. Curaleaf led with an estimated 7.5% citation share, followed by Trulieve at 6.5% and Cookies at 5.5%. Leafly followed at 5.0%, Charlotte’s Web at 4.5%, and Green Thumb Industries and Weedmaps at 3.5% each. Wyld and Stiiizy each took 3.0%, while Kiva Confections, Cresco Labs and Verano Holdings each came in at 2.5%. The remaining roughly 45% of citations were split among ranks 16 through 25, unranked brands and responses that were refused or hedged.

The clearest pattern was that third-party platforms can matter more than retail scale. Leafly and Weedmaps each captured more aggregator citations than every individual MSO except Curaleaf, a sign that AI systems are leaning on brands with broad public footprints, cleaner explanatory language and stronger coverage from outside sources. In a category shaped by local rules and product-specific legality, that structure appears to matter as much as store count.

The policy backdrop is shifting at the same time. The DEA said the Acting Attorney General issued a notice of hearing on April 28, 2026, to transfer marijuana from Schedule I to Schedule III. The hearing is scheduled to begin June 29, 2026, at 9:00 a.m. ET in Arlington, Virginia, and end no later than July 15, 2026. Trulieve said on April 23 that it applauded the Trump administration’s move, and later reported first-quarter 2026 revenue of $287 million, 59% gross margin, $2 million in net income and $100 million in Adjusted EBITDA.

Trulieve also announced on June 5 that its subordinate voting shares were expected to begin trading on the NYSE under ticker TRLV on June 10. For cannabis brands, that kind of visible, structured footprint now matters beyond retail shelves and local search. AI systems are deciding which names are safe enough to repeat, and the brands that win are the ones they can explain without hesitation.